Olema Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2007-01-01
- Employees
- 74
- Market Cap
- $668.8M
- Website
- http://www.olema.com
Clinical Trials
7
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Study of OP-3136 in Advanced or Metastatic Solid Tumors
- Conditions
- Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Interventions
- First Posted Date
- 2025-01-20
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Olema Pharmaceuticals, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT06784193
- Locations
- 🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸University Medical Center - New Orleans, New Orleans, Louisiana, United States
🇺🇸START - Midwest, Grand Rapids, Michigan, United States
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
- Conditions
- Metastatic Breast CancerHER2 Negative Breast CarcinomaBreast CancerAdvanced Breast CancerER Positive Breast Cancer
- Interventions
- First Posted Date
- 2023-08-30
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- Olema Pharmaceuticals, Inc.
- Target Recruit Count
- 510
- Registration Number
- NCT06016738
- Locations
- 🇬🇧
Clinical Trial Site, London, United Kingdom
🇲🇾Clinical Trials Site, Sungai Petani, Kedah, Malaysia
Phase 1b Combo w/ Ribociclib, Alpelisib, or Everolimus
- Conditions
- Metastatic Breast CancerAdvanced Breast CancerER-positive Breast CancerHER2-negative Breast CancerBreast Cancer
- Interventions
- First Posted Date
- 2022-08-19
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Olema Pharmaceuticals, Inc.
- Target Recruit Count
- 155
- Registration Number
- NCT05508906
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸University of California San Francisco Health, San Francisco, California, United States
🇺🇸University of Colorado Cancer Center, Aurora, Colorado, United States
A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2022-03-04
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Olema Pharmaceuticals, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT05266105
- Locations
- 🇦🇺
Site 6108, Waratah, New South Wales, Australia
🇦🇺Site 6104, Westmead, New South Wales, Australia
🇦🇺Site 6102, South Brisbane, Queensland, Australia
A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer
- Conditions
- Hormone Receptor Positive Breast CarcinomaHER2-negative Breast Cancer
- Interventions
- First Posted Date
- 2020-08-10
- Last Posted Date
- 2023-08-22
- Lead Sponsor
- Olema Pharmaceuticals, Inc.
- Target Recruit Count
- 153
- Registration Number
- NCT04505826
- Locations
- 🇺🇸
UCLA Hematology/Oncology, Los Angeles, California, United States
🇺🇸University of Colorado, Aurora, Colorado, United States
🇺🇸University of Miami, Sylvester Comprehensive Cancer Center, Deerfield Beach, Florida, United States
News
Olema's KAT6 Inhibitor OP-3136 Shows Promising Anti-Tumor Activity Across Multiple Cancer Types
• Olema Oncology's novel KAT6 inhibitor OP-3136 demonstrated potent anti-tumor activity in preclinical models of ovarian, prostate, and non-small cell lung cancer, expanding its potential beyond breast cancer. • In ovarian cancer models, OP-3136 achieved sustained tumor regression over 28 days, while showing comparable efficacy to ribociclib in lung cancer models and dose-dependent tumor inhibition in prostate cancer. • The compound exhibited enhanced anti-tumor activity when combined with standard therapies like ribociclib and docetaxel, with patient recruitment currently ongoing in Phase 1 clinical trials.
Olema Oncology Advances Pivotal Phase 3 Trials for Palazestrant in Metastatic Breast Cancer
Olema Oncology is progressing its pivotal Phase 3 OPERA-01 trial of palazestrant monotherapy in second/third-line metastatic breast cancer, with top-line data anticipated in 2026.